Cantharidic_Acid

Cantharidic_Acid

SCHEMBL24226002

C[C@]1(C(=O)O)[C@H]2CC[C@H](O2)[C@@]1(C)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 1.00
TP53 P04637 5/20 1.00
LMNA P02545 4/20 1.00
HIF1A Q16665 3/20 1.00
NPC1 O15118 3/20 1.00
RAB9A P51151 3/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
NFKB1 P19838 3/20 1.00
THPO P40225 3/20 1.00
GMNN O75496 3/20 1.00
PMP22 Q01453 3/20 1.00
MTOR P42345 2/20 1.00
BLM P54132 2/20 1.00
CYP2C19 P33261 1/20 1.00
STAT6 P42226 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
CYP3A4 P08684 3/20 0.41
CYP1A2 P05177 2/20 0.41
TFPI2 P48307 2/20 0.41
KDM4E B2RXH2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cantharidic_Acid SCHEMBL943636 1.00 MAPK1 (1.00) MAPK1TP53LMNAHIF1ANPC1
Cantharidic_Acid SCHEMBL13091537 1.00 MAPK1 (1.00) MAPK1TP53LMNAHIF1ANPC1
SCHEMBL16542813 0.91 MAPK1 (0.83) MAPK1TP53LMNAHIF1ANPC1
SCHEMBL3494225 0.88 MAPK1 (0.77) MAPK1TP53LMNAHIF1ANPC1
SCHEMBL20885049 0.83 MAPK1 (0.70) MAPK1TP53LMNAHIF1ANPC1
SCHEMBL14398404 0.82 MAPK1 (0.67) MAPK1TP53LMNAHIF1ANPC1
SCHEMBL27616131 0.78 MAPK1 (0.61) MAPK1TP53LMNAHIF1ANPC1
SCHEMBL20885003 0.76 MAPK1 (0.59) MAPK1TP53LMNAHIF1ANPC1
Cantharidic_Acid SCHEMBL29360065 0.76 MAPK1 (0.61) MAPK1TP53LMNAHIF1ANPC1
SCHEMBL28493026 0.69 MAPK1 (0.52) MAPK1TP53LMNAHIF1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220024943-A1 HIGH PURITY CANTHARIDIN MANUFACTURING PROCESS AND COMPOSITIONS SOL-GEL TECHNOLOGIES LTD. (IL) 2022-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024943-A1 HIGH PURITY CANTHARIDIN MANUFACTURING PROCESS AND COMPOSITIONS CUTA, TYR, VNN1 MAPK1 2614/4885TP53 3739/4885LMNA 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.